

ANTIDEPRESSANTS - SCORE

Products Affected

- Emsam
- Fetzima
- Fetzima Titration Pack
- Sertraline Hydrochloride CAPS

Details

Criteria	Trial of two generics of the following formulary products: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline (tablet or solution), venlafaxine. Approve for continuation of prior therapy.
-----------------	---

ATYPICAL ANTIPSYCHOTICS - SCORE

Products Affected

- Caplyta
- Fanapt
- Fanapt Titration Pack
- Lybalvi
- Vraylar

Details

Criteria	Trial of two of the following oral generic formulary atypical antipsychotic agents: aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone. Approve for continuation of prior therapy. Step requirement does not apply for Caplyta if request is for depressive episodes associated bipolar I or II disorder.
-----------------	---

Step Therapy Criteria
BCBS-SC PDP BASIC
Effective: 04/01/2022

GLUCAGON- SCORE

Products Affected

- Glucagen Hypokit

Details

Criteria	Trial of one of the following: Gvoke, Baqsimi, or Glucagon
-----------------	--

INVEGA HAFYERA THERAPY - SCORE

Products Affected

- Invega Hafyera

Details

Criteria	Trial of one of the following: Invega Sustenna or Invega Trinza. Step applies to new starts only. Approve for continuation of prior therapy.
-----------------	--

Step Therapy Criteria
BCBS-SC PDP BASIC
Effective: 04/01/2022

NAMZARIC - SCORE

Products Affected

- Namzatic

Details

Criteria	Trial of generic memantine extended-release
-----------------	---

Step Therapy Criteria
BCBS-SC PDP BASIC
Effective: 04/01/2022

NON-PREFERRED SGLT2s - SCORE

Products Affected

- Invokana

Details

Criteria	Trial of Farxiga or Xigduo XR, AND one of the following: Jardiance, Synjardy, Synjardy XR. Step requirements do not apply to members with type 2 diabetes with either diabetic nephropathy or established cardiovascular disease.
-----------------	---

Step Therapy Criteria
BCBS-SC PDP BASIC
Effective: 04/01/2022

PD AGENTS - SCORE

Products Affected

- Neupro

Details

Criteria	Trial of one of the following generic formulary dopamine agonist agent: pramipexole, ropinirole
-----------------	--

Step Therapy Criteria
BCBS-SC PDP BASIC
Effective: 04/01/2022

RELISTOR - SCORE

Products Affected

- Relistor

Details

Criteria	Trial of lubiprostone or lactulose
-----------------	------------------------------------

Step Therapy Criteria
BCBS-SC PDP BASIC
Effective: 04/01/2022

SKIN CANCER AGENTS - SCORE

Products Affected

- Diclofenac Sodium GEL 3%
- Picato

Details

Criteria	Trial of fluorouracil or imiquimod
-----------------	------------------------------------

INDEX

A		Invokana.....6
Antidepressants - Score.....	1	L
Atypical Antipsychotics - Score.....	2	Lybalvi.....2
C		N
Caplyta.....	2	Namzaric.....5
D		Namzaric - Score.....5
Diclofenac Sodium.....	9	Neupro.....7
E		Non-preferred SglT2s - Score.....6
Emsam.....	1	P
F		Pd Agents - Score.....7
Fanapt.....	2	Picato.....9
Fanapt Titration Pack.....	2	R
Fetzima.....	1	Relistor.....8
Fetzima Titration Pack.....	1	Relistor - Score.....8
G		S
Glucagen Hypokit.....	3	Sertraline Hydrochloride.....1
Glucagon- Score.....	3	Skin Cancer Agents - Score.....9
I		V
Invega Hafyera.....	4	Vraylar.....2
Invega Hafyera Therapy - Score.....	4	